Sentinel Lymph Node (SLN) Biopsy for Sebaceous Gland Carcinoma of Eyelid



Status:Recruiting
Conditions:Cancer, Cancer, Ocular
Therapuetic Areas:Oncology, Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:11/16/2018
Start Date:February 2009
End Date:February 2020
Contact:Bita Esmaeli, MD
Phone:713-794-1247

Use our guide to learn which trials are right for you!

Sentinel Lymph Node Localization and Biopsy for Sebaceous Gland Carcinoma of the Eyelid

The goal of this clinical research study is to use sentinel lymph node (SLN - the lymph nodes
closest to the primary tumor that are believed to be at greatest risk for spread of the
disease) mapping to find SLNs and biopsy them to see if you have metastatic disease (cancer
that has spread) that would otherwise have not been found.

If you agree to take part in this study, you will come into the clinic at 2 different times
for lymphatic mapping and SLN mapping/biopsy.

If you are able to become pregnant, blood (about 2 teaspoons) will be drawn for a pregnancy
test, within 7 days before the biopsy. To take part in this study, you must not be pregnant.

Lymphatic mapping is a procedure in which a small amount of a radioactive substance called
Tc99m-Sulfur colloid is injected into the eyelid around the tumor(s) to make the lymph nodes
visible on an imaging scan. After Tc99m-Sulfur colloid is injected, you will have a single
photon emission computed tomography/computed tomography (SPECT/CT) scan performed.

For the SLN biopsy procedure, you will go to the operating room and undergo SLN mapping and
biopsy under general anesthesia. A small amount of Tc99m-Sulfur colloid will again be
injected into the eyelid around the tumor(s), to help the doctor find any possible SLNs. If
you have your tumor removed earlier, the small amount of Tc99m-Sulfur colloid will be
injected into the eyelid around the area of earlier tumor site. Then you will have the SLN
biopsy. To collect the SLN biopsy, the doctor will make a small incision into the tissue over
the lymph nodes that have picked up the Tc99m-Sulfur colloid. The lymph nodes will then be
removed and tested for signs of metastatic disease.

If the biopsy shows signs of metastatic disease, you will receive the standard of care for
metastatic cancer of the eyelid. You will be separately consented for this.

Length of Study:

You will continue to be observed on study for 5 years after the biopsy. You will come to the
clinic for follow-up scans and tests during this time.

Long-Term Follow-Up:

Every 3 months for the first year after the biopsy, and every 6 months after that until 5
years after the biopsy, you will have an eye exam to check the status of the disease.

You will have a head and neck CT or MRI every 6 months for the first year after the biopsy to
make sure the disease has not come back. You will have a chest x-ray 1 year after the biopsy
to make sure the disease has not come back. The head and neck CT or MRI will be repeated 1
time each year for 5 years after the biopsy, as well as whenever the doctor thinks it is
needed.

You will have an ultrasound of lymph nodes in the cheek and neck area 1 year after the
primary tumor was removed to check for metastatic disease.

This is an investigational study. The described procedure for lymphatic mapping and biopsy is
standard of care for other regions of the body. Lymphatic mapping and SLN biopsy for eyelid
cancers are investigational.

Inclusion Criteria:

1. Participant must be 18 years of age or over

2. Possible or suspicious sebaceous gland carcinoma of the eyelid.

3. A CXR (chest x-ray), liver enzymes, and a head and neck CT or magnetic resonance
imaging (MRI) and an ultrasound negative for clinical evidence of metastasis.

4. Patient provided written informed consent. In the event that non-English speaking
participants are eligible for this study, a short form (if applicable) or an ICD in
their language, will be utilized and completed in accordance with the MDACC policy for
Consenting Non-English Speaking Participants.

Exclusion Criteria:

1) Pregnant or nursing females.
We found this trial at
1
site
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
Principal Investigator: Bita Esmaeli, MD
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials